Extensions

U.S. Patent 10,651,866: Term, Application History, and Family Details

An analysis of the prosecution history and continuity data for U.S. Patent No. 10,651,866 ("the '866 patent") provides the following details regarding its term, related applications, and projected expiration.

Patent Term and Expiration:

• Earliest Priority Date: The '866 patent claims priority to U.S. Application No. 15/225,745, which was filed on August 1, 2016.
• Standard Term: U.S. patents have a term of 20 years from the filing date of the earliest U.S. non-provisional application to which they claim priority.
• Patent Term Adjustment (PTA): A review of the patent's file history in the USPTO's Patent Center database indicates zero days of Patent Term Adjustment. The USPTO did not identify any of its own delays during prosecution that would warrant an extension of the patent's term.
• Patent Term Extension (PTE): There is no indication of any Patent Term Extension (PTE) for this patent. PTE is typically granted for delays caused by regulatory review (e.g., by the FDA) and is not applicable here.
• Projected Expiration Date: Based on the earliest priority date of August 1, 2016, and with no term adjustments, the projected expiration date for U.S. Patent No. 10,651,866 is August 1, 2036.

Continuation and Application History:

The '866 patent is part of a chain of "continuation" applications. This means the applicant filed subsequent applications based on the original disclosure to pursue different sets of claims.

• The application that matured into the '866 patent is U.S. Application No. 16/399,867, filed on April 30, 2019.
• This application is a continuation of U.S. Application No. 15/947,845, filed on April 8, 2018.
• The '845 application is, in turn, a continuation of U.S. Application No. 15/225,745, which was filed on August 1, 2016, and has since issued as U.S. Patent No. 9,941,895. This '895 patent is the parent patent in this specific chain.

Related Family Members:

The '866 patent is also related to at least one other U.S. patent through a shared priority claim, forming a larger patent family.

• U.S. Patent No. 11,082,055 B1: This patent, which issued from U.S. Application No. 16/851,044 (filed April 16, 2020), is also listed as part of the family. It shares the same priority date of August 1, 2016. This indicates it is likely another continuation or a divisional application stemming from the same original subject matter.

This network of related applications and patents demonstrates a strategy to build a broad portfolio of intellectual property around the core invention of applying fractional time delays in the oversampled domain.